VKTX Stock: Price, Earnings History and SEC Filings
Viking Therapeutics, Inc. (VKTX) last traded at $27.28, up 1.56% on the latest session and down 16.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.55 against an analyst estimate of $-1.00, a miss of 55.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VKTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 28, 2026 | $-1.55 | $-1.00 | -55.00% |
| Jun 2026 | Jul 29, 2026 | $-1.10 | $-1.21 | +9.09% |
| Mar 2026 | Apr 29, 2026 | $-1.37 | $-0.95 | -44.21% |
| Dec 2025 | Feb 11, 2026 | $-1.38 | $-0.89 | -55.06% |
VKTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How VKTX reacts to earnings
Across its last 8 earnings releases, VKTX moved 3.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-28 | After close | +5.91% |
| 2026-07-29 | After close | -0.96% |
| 2026-04-29 | After close | -0.48% |
| 2026-02-11 | After close | +6.80% |
| 2025-10-22 | After close | +7.96% |
| 2025-07-23 | After close | +0.30% |
| 2025-04-23 | After close | -0.50% |
| 2025-02-05 | After close | -6.09% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VKTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $0 | -$360M | – | – | $-3.19 |
| 2024 | $0 | -$110M | – | – | $-1.01 |
| 2023 | $0 | -$86M | – | – | $-0.91 |
| 2022 | $0 | -$69M | – | – | $-0.90 |
| 2021 | $0 | -$55M | – | – | $-0.71 |
| 2020 | $0 | -$39M | – | – | – |
| 2019 | $0 | -$26M | – | – | – |
| 2018 | $0 | -$22M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VKTX
- 10-Q · Oct 29, 2026
- 8-K · Oct 28, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 28, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 424B5 · Sep 25, 2026
- 424B5 · Sep 25, 2026
- 424B5 · Sep 23, 2026
- 424B5 · Sep 23, 2026
- 8-K · Sep 22, 2026Other events, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
Insider filing activity
VKTX insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VKTX news
- VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?Oct 30, 2026 · finance.yahoo.com
- Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetOct 30, 2026 · finance.yahoo.com
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesOct 29, 2026 · finance.yahoo.com
- LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedOct 29, 2026 · finance.yahoo.com
- Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesOct 29, 2026 · 247wallst.com
- VKTX Q3 Earnings Call Highlights Obesity Pipeline ProgressOct 29, 2026 · finance.yahoo.com
- Viking Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 29, 2026 · app.moby.co
- Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?Oct 29, 2026 · finance.yahoo.com
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.